IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY

被引：2
|
作者：
Emery, P. [1 ]
Bingham, C. O. [2 ]
Burmester, G. -R. [3 ]
Bykerk, V. P. [4 ]
Furst, D. E. [5 ]
Mariette, X. [6 ]
Purcaru, O. [7 ]
Coteur, G. [7 ]
VanLunen, B. [8 ]
Weinblatt, M. [9 ]
机构：
[1] Univ Leeds, Leeds, W Yorkshire, England
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Charite Univ Med Berlin, Berlin, Germany
[4] Hosp Special Surg, Weill Cornell Med Coll, New York, NY 10021 USA
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Univ Paris Sud, Hop Univ Paris Sud, AP HP, Paris, France
[7] UCB Pharma, Brussels, Belgium
[8] UCB Pharma, Raleigh, NC USA
[9] Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.1499
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0165
引用
收藏
页码：712 / 713
页数：2
相关论文
共 50 条
  • [1] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE AND PROGRESSIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
    Emery, P.
    Bingham, C.
    Burmester, G.
    Bykerk, V
    Furst, D.
    Mariette, X.
    Purcaru, O.
    Coteur, G.
    Vanlunen, B.
    Weinblatt, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A707 - A708
  • [2] IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE AND PROGRESSIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE C -EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
    Emery, P.
    Bingham, C.
    Burmester, G. R.
    Bykerk, V. P.
    Furst, D.
    Mariette, X.
    Purcaru, O.
    VanLunen, B.
    Weinblatt, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A710 - A710
  • [3] THE FIRST STUDY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS LED TO SUSTAINED CLINICAL RESPONSE AND INHIBITION OF RADIOGRAPHIC PROGRESSION AT 52 WEEKS: THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
    Emery, P.
    Bingham, C. O.
    Burmester, G. -R.
    Bykerk, V. P.
    Furst, D. E.
    Mariette, X.
    van der Heijde, D.
    Tatla, D.
    Arendt, C.
    Mountian, I.
    VanLunen, B.
    Weinblatt, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 712 - 712
  • [4] Certolizumab Pegol in Combination with Methotrexate in DMARD-Naive Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study
    Weinblatt, Michael
    Bingham, Clifton
    Burmester, Gerd
    Bykerk, V. P.
    Furst, Daniel E.
    Mariette, Xavier
    van der Heijde, Desiree
    Tatla, Daljit
    Arendt, Catherine
    Mountian, Irina
    VanLunen, Brenda
    Emery, Paul
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [5] Reduction of Disease Burden on Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in DMARD-Naive Patients with Active, Severe, Progressive Rheumatoid Arthritis
    Bykerk, V. P.
    Bingham, Clifton
    Burmester, Gerd
    Furst, Daniel E.
    Mariette, Xavier
    Purcaru, Oana
    VanLunen, Brenda
    Weinblatt, Michael
    Emery, Paul
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [6] Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
    Emery, P.
    Bingham, C. O., III
    Burmester, G. R.
    Bykerk, V. P.
    Furst, D. E.
    Mariette, X.
    van der Heijde, D.
    van Vollenhoven, R.
    Arendt, C.
    Mountian, I.
    Purcaru, O.
    Tatla, D.
    VanLunen, B.
    Weinblatt, M. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 96 - 104
  • [7] Assessment of patient-reported outcomes from a double-blind trial of etanercept and methotrexate combination in early active rheumatoid arthritis: The COMET trial
    Durez, P.
    Emery, P.
    Hall, S.
    Koenig, A.
    Sato, R.
    Singh, A.
    Robertson, D.
    Freundlich, B.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S457 - S457
  • [8] IMPROVEMENTS IN PRODUCTIVITY AT PAID WORK AND WITHIN HOUSEHOLD, AND INCREASED PARTICIPATION IN DAILY ACTIVITIES AFTER 24 WEEKS OF CERTOLIZUMAB PEGOL TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY
    Kavanaugh, Arthur
    Gladman, D.
    van der Heijde, Desiree
    Purcaru, O.
    Mease, P.
    [J]. RHEUMATOLOGY, 2013, 52 : 163 - 164
  • [9] IMPROVEMENTS IN PRODUCTIVITY AT PAID WORK AND WITHIN HOUSEHOLD, AND INCREASED PARTICIPATION IN DAILY ACTIVITIES AFTER 24 WEEKS OF CERTOLIZUMAB PEGOL TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A PHASE 3 DOUBLE BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY
    Kavanaugh, A.
    Gladman, D.
    van der Heijde, D.
    Purcaru, O.
    Mease, P.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A228 - A228
  • [10] Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
    Kavanaugh, A.
    Gladman, D.
    van der Heijde, D.
    Purcaru, O.
    Mease, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (01) : 44 - 51
12345